centanafadine capsule for Attention Deficit Hyperactivity Disorder (ADHD)

"The age range that is eligible for this clinical trial according to the current criteria is 4 to 12 years old."

"That is correct. The website provides updated information that recruitment is ongoing for the 450 patients at a single site."

"That is correct, the clinical trial mentioned is currently looking for patients. As seen on clinicaltrials.gov, the posting went up on 7/11/2022 and was updated as recently as 8/31/2022. They are aiming to have 450 people sign up in total from 1 location."

"This study is looking for 450 young patients that have hyperkinesis. In order to be eligible, potential participants must meet the following requirements: They must be between 4 and 12 years old (inclusive), have a primary diagnosis of ADHD based on DSM-5 criteria as confirmed with the MINI-KID, have a minimum symptoms total raw score of ≥ 28 on the ADHD-RS-5 at baseline, score 4 or higher on the CGI-S-ADHD at baseline, and if they are aged 4 or 5 years only: has failed adequate psychotherapy or in the investigator's opinion, is severe enough to"

"Centanafadine capsule safety is rated a 3 because it has undergone Phase 3 clinical trials. This indicates that, while more research needs to be done, the drug's efficacy has been supported and multiple rounds of data support its safety."